FDA Swaps ‘Animal Testing’ for ‘Nonclinical’ in Rules

FDA has issued a direct final rule striking the words “animal test” and “animal study” from its human drug and biological-product regulations and replacing them with “nonclinical test” and “nonclinical study” — a vocabulary change written into binding regulatory text, not just guidance. The rule, docketed FDA-2026-N-5347, issued 21 September 2026 and published in the Federal Register the following day, adds a formal definition broad enough to cover cell-based assays, organs-on-chips, and computer models alongside traditional animal studies, which remain fully permitted.

A procedural wrinkle: two rules, one purpose

FDA used the direct-final-rule mechanism, which lets an agency finalize a rule without the normal proposed-rule comment-and-response cycle when it expects the change to be uncontroversial. As a procedural fail-safe, FDA simultaneously issued a companion proposed rule covering identical substance. If the direct final rule draws no significant adverse comments during the window that closes 7 December 2026, FDA lets it take effect on its own; independent trade-press reporting on the docket puts the target effective date at 4 February 2027. If FDA does receive significant adverse comments, it has said it will withdraw the direct final rule and instead proceed through ordinary notice-and-comment rulemaking on the companion proposed rule — giving the agency a route to the same destination either way, on a timeline that depends on how the public reacts.

What the definition actually says

The rule's operative text defines nonclinical test and nonclinical study to mean “a test or study conducted in vitro, in silico, or in chemico, or a nonhuman in vivo test or study.” Read closely, that last clause — nonhuman in vivo test or study — is simply an animal study by another name. FDA is explicit that the rule adds no new requirements, does not eliminate or prohibit animal studies, and does not change the evidentiary bar for any application. What changes is that the regulatory text no longer treats animal testing as the default method with everything else carved out as an exception; instead, in vitro assays, computer modeling, and nonhuman in vivo work sit inside a single defined category that a sponsor can draw from based on which method best answers the scientific question at hand.

The 2022 law behind it

FDA frames the rule as implementing the FDA Modernization Act 2.0, enacted in December 2022, which amended the Federal Food, Drug, and Cosmetic Act to allow sponsors to use non-animal New Approach Methodologies — human biology-based cell assays, organs-on-chips and other microphysiological systems, and computer or AI-based models — to generate evidence supporting an investigational new drug application, rather than requiring animal data by default. That 2022 law changed the statute; this rule is FDA rewriting its own regulations to match the statutory language nearly three years later. Alongside the rule, FDA published an initial New Approach Methodologies (NAMs) Database of Use Case Examples, drawn from the agency's own application-review files, and separately said it has selected the American Type Culture Collection to help advance microphysiological-systems and organoid-based platforms for infectious disease and cancer research.

What it means for sponsors

• The rule is a terminology and definitional change across FDA's existing drug and biologic regulations, not a new testing requirement or a new approval standard.
• Every IND, NDA, and BLA sponsor's nonclinical/toxicology package is now written against regulations that name “nonclinical” methods rather than “animal” methods as the baseline category — a framing shift with no immediate compliance action required.
• Acting FDA Commissioner Kyle Diamantas said in the agency's announcement: “This new rule supports the Trump Administration's push to explore ways to complement, or where appropriate, replace animal studies with methods that may better predict how medicines will actually affect people.”
• The rule does not resolve the harder question sponsors still face case by case: how much analytical, in vitro, or computational evidence a specific review division will accept in place of animal data for a specific product — that determination remains made application by application.

Frequently asked questions

What did FDA do?

FDA issued a direct final rule, "Nonclinical Testing Terminology" (Docket FDA-2026-N-5347), on 21 September 2026, publishing it in the Federal Register on 22 September. It replaces "animal test(s)" and "animal study/studies" throughout FDA's human drug and biological-product regulations with "nonclinical test(s)" and "nonclinical study/studies," and adds a formal regulatory definition of the new terms.

Does this ban or reduce animal testing?

No. FDA states the rule adds no new requirements, does not eliminate or prohibit animal studies, and does not change evidentiary standards. The new definition of "nonclinical test and nonclinical study" explicitly includes nonhuman in vivo tests — meaning animal studies remain fully acceptable — alongside in vitro, in silico, and in chemico methods.

Why is FDA doing this now?

FDA frames the rule as implementing the 2022 FDA Modernization Act 2.0, which directed the agency to recognize New Approach Methodologies (NAMs) — human cell-based assays, organs-on-chips and other microphysiological systems, and computer models — as scientifically acceptable alternatives for nonclinical safety testing, rather than exceptions to an animal-testing default. Alongside the rule, FDA published an initial NAMs Database of Use Case Examples and said it selected the American Type Culture Collection (ATCC) to help advance microphysiological-systems and organoid platforms for infectious disease and cancer research.

When does it take effect?

FDA used the direct-final-rule mechanism, paired with a companion proposed rule as a procedural fallback. Comments are due 7 December 2026. If FDA receives no significant adverse comments, the direct final rule is expected to take effect 4 February 2027; if it does receive significant adverse comments, FDA says it will withdraw the direct final rule and proceed instead through standard notice-and-comment rulemaking on the companion proposed rule.